Stay Up to Date
Breaking News,
Updates, & More
Click Here to
Subscribe

Noncompliance with Granulocyte Colony-Stimulating Factor Guidelines Has Consequences

TOP - May 2017, Vol 10, No 2 - NCCN News, NCCN
Audrey Andrews

Orlando, FL—Compliance with orders for granulocyte colony-stimulating factors (G-CSFs) is suboptimal, and inadequate prophylaxis was directly tied to hospital admissions, according to results of a recent clinical trial from the University of Pennsylvania Health System.

At the National Comprehensive Cancer Network (NCCN) 22nd Annual Conference, Julianne Hibbs, DO, Internist, Pennsylvania Hospital, Philadelphia, described the use of G-CSF in 93 patients who developed febrile neutropenia. She reported that 18% of this group should have received G-CSF, but did not, and their average length of stay for febrile neutropenia was approximately 4 days longer than patients who received these drugs appropriately.

“The length of stay for patients who did not receive G-CSF and met ASCO [American Society of Clinical Oncology] criteria was notably longer compared with the other subgroups. These patients had extended hospital stays, which may represent more severe infections, greater morbidity, and higher healthcare costs,” she said.

Febrile neutropenia contributes significantly to the morbidity, mortality, and cost of caring for patients with cancer, but its incidence is reduced by the use of G-CSFs. Dr Hibbs and her team conducted the single-center, retrospective study to evaluate oncologists’ compliance with ASCO guidelines for the appropriate use of G-CSF prophylaxis, and to determine whether noncompliance impacts the length of stay in patients developing febrile neutropenia.

Study of Patients with Febrile Neutropenia

The researchers identified 93 patients who developed febrile neutropenia as a direct complication of chemotherapy over a 2-year period. Based on ASCO guidelines for G-CSF use, they created 4 subgroups, which included patients who received G-CSF and met ASCO criteria (60%), did not receive G-CSF although they met ASCO criteria (18%), did not receive G-CSF and did not meet ASCO criteria (21%), or received G-CSF but did not meet ASCO criteria (1%).

“We determined that compliance with G-CSF administration impacted length of hospital stay,” she reported. Mean length of stay for the 4 subgroups was 8.7 days, 13.1 days, 6.2 days, and 9.2 days, respectively.

Of the 16 patients who should have received G-CSF but did not, 8 met the criteria because they received chemotherapy regimens with >20% risk for febrile neutropenia. The other 8 (10%-20%) received intermediate-risk regimens, but had ≥1 of 7 risk factors that warrant treatment (eg, bone marrow involvement, persistent neutropenia, recent surgery or open wound, bilirubin >2 mg/dL, creatinine clearance <50%, age >65 years), Dr Hibbs noted.

“In our study, noncompliance with ASCO guidelines for prophylactic G-CSF use was seen equally in patients with high febrile neutropenia risk from their chemotherapy regimen, and in patients with personal risk factors,” she said.

The differences among the groups were not significant, she noted, “but this was thought to be secondary to the small patient population and lack of statistical power. The trend of the data demonstrates clinical relevance and warrants further investigation with a larger patient population.”

These results emphasize the need for effective risk-stratification tools, as well as adherence to G-CSF prophylaxis to improve patient outcomes, as directed by national and international guidelines, Dr Hibbs added.

Related Items
Explosion of New Regimens for Multiple Myeloma: Selecting the Right Option for the Right Patient
Patricia Stewart
TON - December 2020, Vol 13, No 6 published on December 23, 2020 in NCCN
Aggressive Approach to High-Risk Smoldering Myeloma Gains Consensus
Patricia Stewart
TON - December 2020, Vol 13, No 6 published on December 23, 2020 in NCCN
CAR T-Cell Therapy May Not Be Needed for Select Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Patricia Stewart
TON - December 2020, Vol 13, No 6 published on December 23, 2020 in NCCN
Strategies for Lowering the Cost of Cancer Care
William King
TOP - November 2020 Vol 13, No 6 published on November 9, 2020 in NCCN
The Impact of COVID-19 on the Oncology Care Model
William King
TOP - November 2020 Vol 13, No 6 published on November 9, 2020 in NCCN
Experts Agree That Innovation Is Key to Improving Value-Based Care
William King
TOP - November 2020 Vol 13, No 6 published on November 9, 2020 in NCCN
FDA on In Vitro Diagnostics, Vaping; Cost of Novel Treatments
Web Exclusives published on October 15, 2019 in FDA Updates, In the News, NCCN, NCCN News
Updated NCCN Breast Cancer Guideline Expands Treatment Recommendations for HR-Positive, HER2-Negative Disease
Wayne Kuznar
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in Breast Cancer, NCCN
Immunotherapy Strategies in the Updated NCCN Guideline for NSCLC Hinge on PD-L1 Testing
Wayne Kuznar
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in NCCN
Updated NCCN Treatment Guideline for CML Establishes Criteria for Stopping TKI Therapy
Wayne Kuznar
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in NCCN
Last modified: April 27, 2020